# | Title | Journal | Year | Citations |
---|
|
1 | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial | Lancet, The | 2016 | 783 |
2 | Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy | JAMA Oncology | 2018 | 589 |
3 | Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer | Cancer Discovery | 2020 | 480 |
4 | Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer | Nature Medicine | 2022 | 285 |
5 | Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial | Annals of Oncology | 2019 | 137 |
6 | NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis | Journal of Thoracic Oncology | 2020 | 101 |
7 | Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC | New England Journal of Medicine | 2023 | 85 |
8 | RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis—an updated review | Cell Death and Disease | 2019 | 54 |
9 | Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort | Clinical Lung Cancer | 2019 | 50 |
10 | Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy | JCO Precision Oncology | 2020 | 27 |
11 | Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment | European Respiratory Journal | 2017 | 22 |
12 | MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial | British Journal of Cancer | 2019 | 20 |
13 | Effect of cannabis and tobacco on emphysema in patients with spontaneous pneumothorax | Diagnostic and Interventional Imaging | 2018 | 18 |
14 | The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma | Lung Cancer | 2014 | 17 |
15 | Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial | Annals of Oncology | 2017 | 17 |
16 | Prophylactic radiotherapy to prevent procedure-tract metastases | Lancet Oncology, The | 2016 | 14 |
17 | Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial | Clinical Cancer Research | 2019 | 13 |
18 | Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas | Journal of Molecular Diagnostics | 2019 | 12 |
19 | Detection of secondary causes of spontaneous pneumothorax: Comparison between computed tomography and chest X-ray | Diagnostic and Interventional Imaging | 2020 | 11 |
20 | Feasibility of spirometry in primary care to screen for COPD: a pilot study | International Journal of COPD | 2016 | 8 |
21 | Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP | Targeted Oncology | 2022 | 8 |
22 | Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study | ESMO Open | 2022 | 7 |
23 | Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial | Cancers | 2019 | 5 |
24 | Osimertinib in first-line treatment—is a comparison not proof? | Annals of Translational Medicine | 2018 | 3 |
25 | Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial? | European Respiratory Journal | 2016 | 1 |
26 | Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer | Diagnostic and Interventional Imaging | 2018 | 1 |
27 | RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome | Journal of Thoracic Oncology | 2019 | 1 |
28 | 671 Update of a systematic review and meta-analysis studying the association between antibiotic use and clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors | | 2020 | 0 |